Brucellosis Vaccine Market Size, Share & Trends Report, 2022-2030
The global Brucellosis Vaccine market gathered revenue around USD 265.1 Million in 2021 and market is set to grow USD 390.4 Million by the end of 2030 and is estimated to expand at a modest CAGR of 4.2% during the prediction period 2022 to 2030.
Growth Factors:
Brucellosis is an extremely transmissible zoonotic infection. Brucella are transferred from animals to humans through the consumption of infected foodstuff, undercooked meat, or unpasteurized milk from diseased animals; direct contact with an infected animal or their discharges, or inhalation of aerosols. Different types of vaccine are available for brucellosis including RB51 vaccine and S19 vaccine. The global brucellosis vaccine market is driven by rise in prevalence of brucellosis and increase in investments by government bodies.
Asia Pacific dominated the global brucellosis vaccine market in 2020, and the trend is anticipated to continue during the forecast period. Increase in livestock population, launch of new products, high prevalence rate of brucellosis, and presence of major players are expected to propel the brucellosis vaccine market in Asia Pacific during the forecast period. Asia Pacific is likely to be a highly lucrative market for brucellosis vaccines during the forecast period. The market in the region is likely to expand at a high CAGR from 2022 to 2030.
Report Scope of the Brucellosis Vaccine Market
|
Report Coverage |
Details |
|
Market Size |
US$ 265.1 Million by 2030 |
|
Growth Rate |
CAGR of 4.2% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Product, Source, Application, End-user and Region, |
|
Companies Mentioned |
STEMCELL Technologies, Inc., Astellas Pharma, Inc., Cellular Engineering Technologies, Inc., BioTime, Inc., Takara Bio, Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics, Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc. |
Rise in Prevalence of Brucellosis and Increase in Investments by Government Bodies to Drive Global Market
Increase in the number of animals suffering from brucellosis is projected to boost the growth of the global brucellosis vaccine market from 2021 to 2031. Globalization and climate change lead to outbreak of animal diseases; some of these are transmissible to humans. According to the IFAH Europe, rise in global temperatures leads to appearance of new diseases and helps other diseases to reappear. Most human zoonotic infections are transmitted by livestock. Zoonotic diseases account for 61% of the total animal diseases. Increase in livestock population in countries such as India and China is anticipated to drive the demand for brucellosis vaccines in the near future.
Government initiatives play an important role in the growth of the animal healthcare segment. For instance, compulsory immunization policy in China, availability of affordable veterinary vaccines, awareness programs & funding for research & development are expected to drive the global veterinary healthcare market. The Animal and Plant Health Agency (APHA) received US$ 100,000 in the AgResults’ Brucellosis Vaccine Prize competition, aimed at incentivizing the development of a vaccine that is effective, safe, and viable for use against brucella melitensis in small ruminants across the developing world.
RB51 Vaccine to Dominate Brucellosis Vaccine Market
In terms of type, the global brucellosis vaccine market has been classified into RB51 vaccine, S19 vaccine, and others. The RB51 vaccine segment dominated the global brucellosis vaccine market in 2020, and the trend is expected to continue during the forecast period. RB51 vaccine is the most common vaccine used for brucellosis. Vaccination of pregnant cows with strain RB51 can induce low levels of abortion (less than 0.2%); however, it is safe at lower doses during pregnancy. This is likely to propel the segment during the forecast period. Additionally, increase in preference for RB51 vaccine over others due to high efficiency in low dose is projected to augment the segment in the next few years.
DNA Vaccine Held Significant Market Share in 2020
Based on vaccine type, the global brucellosis vaccine market has been categorized into DNA vaccine, subunit vaccine, vector vaccine, and recombinant vaccine. The DNA vaccine segment led the global brucellosis vaccine market in terms of revenue in 2020 and the trend is anticipated to continue during the forecast period. DNA vaccination provided a new and valuable approach to the development of brucellosis vaccines and offered advantages in flexibility of design, speed, simplicity of production, and the ability to elicit both cellular and humoral immune responses. This factor is expected to fuel the growth of the segment during the forecast period.
Cattle to be Highly Lucrative Application
In terms of application, the global brucellosis vaccine market has been segregated into cattle, sheep & goat, and others. The segment is likely to account for significant market share during the forecast period due to the high usage of these vaccines for cattle. Additionally, increase in cattle population in countries such as India and Brazil is projected to propel the segment over the next few years. According to study, Brazil had around 145 million cattle in 2020.
Veterinary Hospitals & Clinics to be Major Distribution Channel
Based on distribution channel, the global brucellosis vaccine market has been divided into veterinary hospitals & clinics, retail channels, and others. The veterinary hospitals & clinics segment led the global brucellosis vaccine market in terms of revenue in 2020. The trend is projected to continue during the forecast period due to increase in inclination of owners to avail various vaccines that veterinary clinics offer and rise in preference for veterinary hospitals & clinics for vaccination.
Asia Pacific to Dominate Brucellosis Vaccine Market
In terms of region, the global brucellosis vaccine market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific dominated the global brucellosis vaccine market in 2020, followed by Europe. Asia Pacific's large market share can be ascribed to increase in livestock population, rise in number of brucellosis cases, less awareness about diseases, new product launches, and presence of major players.
The brucellosis vaccine market in Asia Pacific is anticipated to expand at a high CAGR from 2022 to 2030. This can be ascribed to the presence of developing countries with commercial hubs, expanding business organizations, improving health care infrastructure, and increase in investments by companies.
Some of the prominent players in the Brucellosis Vaccine Market include: Merck Animal Health, Ceva Sante Animale, CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd., Hester Biosciences Limited, Veterinary Technologies Corporation, Fivet Animal Health, Jordan Bio-industries Center, and Laboratories Tornel.
Segments Covered in the Report
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Points Covered in Brucellosis Vaccine Market Study:
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers